Aurinia Pharmaceuticals Inc.
Aurinia exists to make a difference. Our mission is to transform people’s lives by delivering therapeutics that change the course of autoimmune disease. From the earliest days of the company, we’ve applied a creative, thoughtful and responsible approach to developing therapies for people in need. In addition to driving adoption of our approved therapy for appropriate people with lupus nephritis, we are also actively pursuing a broader portfolio of innovative drugs for autoimmune disease. Our strategy leverages the skills and knowledge of our incredible team and our deep experience in principled drug development and commercialization. Together, we are driven to make an impact for our patient communities as advocates and partners in innovation.
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
We are committed to transforming people’s lives by delivering therapeutics that change the course of autoimmune disease. This area includes many of the most challenging and burdensome chronic diseases for global healthcare systems, and on an individual level they often have significant impacts on quality of life.
Through scientific and clinical excellence, deep engagement with patient communities and commercial expertise, we are building our leadership in specialty pharmaceuticals for autoimmune disease to deliver long-term value to patients and the healthcare system.